{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:24:14Z","timestamp":1792621454997,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["R01DK130266"],"award-info":[{"award-number":["R01DK130266"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["R01DK121904"],"award-info":[{"award-number":["R01DK121904"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100022939","name":"Zell Family Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100022939","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2025,4]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Higher body mass index increased risk of progression to ESKD in patients with early-stage autosomal dominant polycystic kidney disease.<\/jats:p>\n <\/jats:list-item>\n \n Higher body mass index did not increase the risk of progression to ESKD in patients with late-stage autosomal dominant polycystic kidney disease.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Prior research has linked higher body mass index (BMI) and greater visceral adiposity with more rapid progression of early-stage autosomal dominant polycystic kidney disease (ADPKD). We now evaluate the association between overweight and obesity in patients with early- and late-stage ADPKD with progression to ESKD.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Participants with early-stage ADPKD (study A;\n N<\/jats:italic>\n =556; eGFR: 91\u00b117 ml\/min per 1.73 m\n 2<\/jats:sup>\n ) and late-stage ADPKD (study B;\n N<\/jats:italic>\n =483; eGFR: 48\u00b112 ml\/min per 1.73 m\n 2<\/jats:sup>\n ) who participated in the Halt Progression of Polycystic Kidney Disease (HALT) polycystic kidney disease trials were categorized by BMI as normal weight (18.5\u201324.9 kg\/m\n 2<\/jats:sup>\n ; ref;\n n<\/jats:italic>\n =357), overweight (25.0\u201329.9 kg\/m\n 2<\/jats:sup>\n ;\n n<\/jats:italic>\n =384), or obese (\u226530 kg\/m\n 2<\/jats:sup>\n ;\n n<\/jats:italic>\n =298). Kaplan\u2013Meier survival analysis and multivariate Cox proportional hazard models were used to determine the association of baseline BMI as a continuous and categorical variable with risk of ESKD (according to the United States Renal Data System) over a median (interquartile range) follow-up period of 12.2 (7.5\u201313.3; study A) and 7.3 (5.1\u201311.7; study B) years (primary outcome). All-cause mortality (National Death Index) was also considered as a competing risk (Fine and Gray method).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The number of ESKD events was greater with overweight (\n n<\/jats:italic>\n =24) and obesity (\n n<\/jats:italic>\n =23) in HALT study A versus normal weight (\n n<\/jats:italic>\n =12) but not in HALT study B (normal weight:\n n<\/jats:italic>\n =89, overweight:\n n<\/jats:italic>\n =102, obese:\n n<\/jats:italic>\n =92). In fully adjusted models, higher BMI was associated with risk of progression to ESKD in study A (hazard ratio [HR (95% confidence interval)], 1.09 [1.03 to 1.15] per unit higher BMI) but not in study B (HR, 0.98 [0.96 to 1.00]). Obesity was associated with increased risk of ESKD (HR, 2.71 [1.22 to 6.02] versus normal weight) in study A only. Results were similar when considering death as a competing risk.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Higher BMI, particularly obesity, increased the risk of progression to ESKD in patients with early-stage ADPKD but not in those with late-stage ADPKD.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.0000000640","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T12:00:27Z","timestamp":1739966427000},"page":"520-528","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.2215","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-3256","authenticated-orcid":false,"given":"Kristen L.","family":"Nowak","sequence":"first","affiliation":[{"name":"Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-3576","authenticated-orcid":false,"given":"Timothy P.","family":"Copeland","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine University of California-San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-2526","authenticated-orcid":false,"given":"Elaine","family":"Ku","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine University of California-San Francisco, San Francisco, California"},{"name":"Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-6302","authenticated-orcid":false,"given":"Mark J.","family":"Sarnak","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7457-6497","authenticated-orcid":false,"given":"Berenice","family":"Gitomer","sequence":"additional","affiliation":[{"name":"Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleab Z.","family":"Abebe","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, and Center for Biostatistics and Qualitative Methodology, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6030-8694","authenticated-orcid":false,"given":"Arlene","family":"Chapman","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Department of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4963-1132","authenticated-orcid":false,"given":"Ronald","family":"Perrone","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-4880","authenticated-orcid":false,"given":"Frederic F.","family":"Rahbari-Oskoui","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Steinman","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1776-2533","authenticated-orcid":false,"given":"Alan S.L.","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Chonchol","sequence":"additional","affiliation":[{"name":"Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"10","key":"B1-20250428","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2215\/CJN.05360522","article-title":"Current challenges and perspectives on developing a clinical trial design for ADPKD","volume":"17","author":"Ostroff","year":"2022","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"B2-20250428","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B3-20250428","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2215\/CJN.16871020","article-title":"Overweight and obesity and progression of ADPKD","volume":"16","author":"Nowak","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"B4-20250428","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1053\/j.ajkd.2024.02.014","article-title":"Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial","volume":"84","author":"Nowak","year":"2024","journal-title":"Am J Kidney Dis."},{"issue":"24","key":"B5-20250428","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"New Engl J Med."},{"issue":"6","key":"B6-20250428","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"Analysis of baseline parameters in the HALT polycystic kidney disease trials","volume":"81","author":"Torres","year":"2012","journal-title":"Kidney Int."},{"issue":"1","key":"B7-20250428","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT polycystic kidney disease trials: design and implementation","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"issue":"24","key":"B8-20250428","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"New Engl J Med."},{"issue":"5","key":"B11-20250428","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ki.2014.376","article-title":"Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease","volume":"87","author":"Ku","year":"2015","journal-title":"Kidney Int."},{"issue":"9","key":"B12-20250428","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating pkd1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B13-20250428","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ekir.2022.02.009","article-title":"Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD","volume":"7","author":"Zhou","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"9569","key":"B14-20250428","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet."},{"issue":"3","key":"B15-20250428","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2215\/CJN.04071206","article-title":"Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease","volume":"2","author":"Wahba","year":"2007","journal-title":"Clin J Am Soc Nephrol."},{"issue":"12","key":"B16-20250428","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1093\/ndt\/gfaa182","article-title":"Volume overload in hemodialysis: diagnosis, cardiovascular consequences, and management","volume":"36","author":"Loutradis","year":"2021","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B17-20250428","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.ki.5002586","article-title":"Association between obesity and kidney disease: a systematic review and meta-analysis","volume":"73","author":"Wang","year":"2008","journal-title":"Kidney Int."},{"issue":"1","key":"B18-20250428","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-144-1-200601030-00006","article-title":"Body mass index and risk for end-stage renal disease","volume":"144","author":"Hsu","year":"2006","journal-title":"Ann Intern Med."},{"issue":"4","key":"B19-20250428","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.kint.2017.03.019","article-title":"Increased body mass index is a risk factor for end-stage renal disease in the Chinese Singapore population","volume":"92","author":"Lew","year":"2017","journal-title":"Kidney Int."},{"issue":"4 Pt 1","key":"B20-20250428","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.HYP.25.4.587","article-title":"Early predictors of 15-year end-stage renal disease in hypertensive patients","volume":"25","author":"Perry","year":"1995","journal-title":"Hypertension."},{"issue":"4","key":"B21-20250428","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/01.EDE.0000071413.55296.c4","article-title":"Lifestyle factors, obesity and the risk of chronic kidney disease","volume":"14","author":"Stengel","year":"2003","journal-title":"Epidemiology."},{"key":"B22-20250428","first-page":"S169","article-title":"Predictors of end-stage renal disease and body mass index in a screened cohort","volume":"63","author":"Iseki","year":"1997","journal-title":"Kidney Int Suppl."},{"issue":"5","key":"B23-20250428","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/ajcn\/nqy200","article-title":"Obesity and risk of end-stage renal disease in patients with chronic kidney disease: a cohort study","volume":"108","author":"Lin","year":"2018","journal-title":"Am J Clin Nutr."},{"issue":"1","key":"B24-20250428","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12882-019-1434-7","article-title":"Obesity is not associated with progression to end stage renal disease in patients with biopsy-proven glomerular diseases","volume":"20","author":"Elyan","year":"2019","journal-title":"BMC Nephrol."},{"issue":"3","key":"B25-20250428","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ekir.2020.12.016","article-title":"Characteristics of patients with end-stage kidney disease in ADPKD","volume":"6","author":"Shukoor","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"2","key":"B26-20250428","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pcad.2018.07.001","article-title":"Obesity paradox in advanced kidney disease: from bedside to the bench","volume":"61","author":"Naderi","year":"2018","journal-title":"Prog Cardiovasc Dis."},{"issue":"3","key":"B27-20250428","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","article-title":"Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease","volume":"2","author":"Perrone","year":"2017","journal-title":"Kidney Int Rep."},{"issue":"3","key":"B28-20250428","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2017.09.027","article-title":"Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease","volume":"93","author":"Yu","year":"2018","journal-title":"Kidney Int."},{"issue":"4","key":"B29-20250428","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2215\/CJN.13291019","article-title":"Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential","volume":"15","author":"Nowak","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"B30-20250428","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food restriction ameliorates the development of polycystic kidney disease","volume":"27","author":"Warner","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B31-20250428","doi-asserted-by":"crossref","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","article-title":"A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease","volume":"310","author":"Kipp","year":"2016","journal-title":"Am J Physiol Renal Physiol."},{"issue":"1","key":"B32-20250428","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/kidneydial2010013","article-title":"Obesity, weight loss, lifestyle interventions, and autosomal dominant polycystic kidney disease","volume":"2","author":"Steele","year":"2022","journal-title":"Kidney Dial."},{"issue":"1","key":"B33-20250428","doi-asserted-by":"crossref","first-page":"103697","DOI":"10.1016\/j.isci.2021.103697","article-title":"Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease","volume":"25","author":"Hopp","year":"2022","journal-title":"iScience."},{"issue":"9","key":"B34-20250428","doi-asserted-by":"crossref","first-page":"832.e7","DOI":"10.1016\/j.amjmed.2012.12.018","article-title":"Changing referral characteristics of patients with autosomal dominant polycystic kidney disease","volume":"126","author":"Helal","year":"2013","journal-title":"Am J Med."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:48Z","timestamp":1786369548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000640","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"2024-08-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}